11:34 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

ErepoXen: Additional Ph II data

Top-line data from 14 patients with CKD in the third cohort of an open-label, South African and Australian Phase II trial showed that ErepoXen every 2 weeks led to increased hemoglobin levels in 79% of...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

ErepoXen: Phase II data

Data from 12 adults with CKD who are not receiving dialysis in the second cohort of an open-label, New Zealand and Australian Phase II trial showed that biweekly ErepoXen led to increased hemoglobin levels in...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Xenetic hematology news

In 1Q14, U.K.-based Xenetic Biosciences plc became U.S.-based Xenetic Biosciences Inc. In January, Xenetic Biosciences plc delisted from LSE and completed a reverse merger with Xenetic Biosciences Inc. (formerly General Sales and Leasing Inc.). In...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

General Sales and Leasing, Xenetic Biosciences deal

The boards of the companies agreed on a proposal under which GSL will acquire Xenetic. Under the proposal, Xenetic shareholders will receive 56 GSL shares for every 175 Xenetic shares held. The companies said the...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

ErepoXen: Phase II started

Xenetic began an open-label, New Zealand and Australian Phase II trial to evaluate multiple doses of ErepoXen in up to 72 adults with CKD who are not receiving dialysis or erythropoiesis-stimulating agents (ESAs). SynBio has...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

General Sales & Leasing Inc. (GSL), Xenetic Biosciences deal

GSL made a non-binding offer to acquire the share capital of Xenetic Biosciences. Xenetic's ErepoXen is a long-acting erythropoietin (EPO) in Phase II testing for anemia in chronic kidney disease (CKD). GSL owned and operated...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

ErepoXen: Phase II started

This month, Xenetic will begin an open-label, New Zealand and Australian Phase II trial to evaluate multiple doses of ErepoXen in up to 72 adults with CKD who are not receiving dialysis or erythropoiesis-stimulating agents...
07:00 , May 20, 2013 |  BC Week In Review  |  Clinical News

ErepoXen: Phase III started

Xenetic said partner SynBio began a 24-month, open-label, Russian Phase III trial comparing ErepoXen vs. Aranesp darbepoetin alfa in 150 patients with stage 3 or 4 CKD. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Aranesp....
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

ErepoXen: Phase I/IIa started

Xenetic said its partner the Serum Institute began an open-label, Indian Phase I/IIa trial to evaluate IV ErepoXen in 40 chronic renal failure patients on dialysis. Xenetic and the Serum Institute are co-developing the compound,...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Company News

Xenetic Biosciences, Serum Institute of India deal

The companies mutually terminated an amended July 2004 deal. The Serum Institute of India (SIIL) returned rights to Xenetic 14 products under the deal, including a preclinical 13 valent pneumococcal vaccine and StimuXen . Xenetic...